Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares RepurchasedWages, Salaries and Other
Ratios

BridgeBio Pharma (BBIO) Long-Term Debt Issuances: 2019-2025

  • BridgeBio Pharma's Long-Term Debt Issuances rose 27.78% to $575.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.3 billion, marking a year-over-year increase of 31.61%. This contributed to the annual value of $450.0 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q1 2025, BridgeBio Pharma's Long-Term Debt Issuances is $575.0 million, which was up 27.78% from $450.0 million recorded in Q1 2024.
  • In the past 5 years, BridgeBio Pharma's Long-Term Debt Issuances registered a high of $747.5 million during Q1 2021, and its lowest value of $450.0 million during Q1 2024.
  • Over the past 2 years, BridgeBio Pharma's median Long-Term Debt Issuances value was $512.5 million (recorded in 2024), while the average stood at $512.5 million.
  • Data for BridgeBio Pharma's Long-Term Debt Issuances shows a peak YoY soared of 35.91% (in 2021) over the last 5 years.
  • BridgeBio Pharma's Long-Term Debt Issuances (Quarterly) stood at $747.5 million in 2021, then reached $450.0 million in 2024, then rose by 27.78% to $575.0 million in 2025.
  • Its last three reported values are $575.0 million in Q1 2025, $450.0 million for Q1 2024, and $747.5 million during Q1 2021.